Literature DB >> 33770382

Reduced fibroblast growth factor 21 and β-Klotho secretion in untreated congenital isolated GH deficiency.

Alécia A Oliveira-Santos1, Roberto Salvatori2, Ana C Bueno3, Monica C Nogueira3, Viviane C Campos1, Manuela A Melo1, Carla R P Oliveira1, Cynthia S Barros-Oliveira1, Cindi G Marinho1, Nayra P Damascena1, Elenilde G Santos1, Enaldo V Melo1, Francisco J A de Paula3, Margaret de Castro3, Manuel H Aguiar-Oliveira1.   

Abstract

PURPOSES: Increasing evidence suggests that the FGF-Klotho endocrine system and the somatotropic system (pituitary and extra-pituitary GH) may have important metabolic and immune relationships, thus contributing to the pathophysiology of aging-related disorders, including diabetes, atherosclerosis, and cancer. The status of these interactions in isolated GH deficiency (IGHD) is unknown. The objective of this study was to assess the response of both FGF21 and β-Klotho levels to a standard meal in a homogeneous group of adults with congenital untreated IGHD due to a homozygous mutation in the GHRH receptor gene.
METHODS: In a cross-sectional study, we measured the levels of FGF21 and β-Klotho, before and 30, 60, 120, and 180 min after a standardized test meal in 20 (11 males) IGHD and 20 (11 males) age-matched controls. Areas under the curves (AUC) of FGF21 and β-Klotho were calculated.
RESULTS: Baseline levels of FGF21 were similar, but baseline levels of β-Klotho were lower in IGHD subjects. The IGHD individuals exhibited lower AUC for FGF21 and β-Klotho levels than control subjects. There was a positive correlation between IGF1 and β-Klotho levels in the pooled groups. No correlation was found between IGF1 and FGF21 levels.
CONCLUSIONS: Subjects with lifetime, untreated IGHD exhibit reduced FGF21 and β-Klotho levels response to a mixed meal. This difference may have consequences on metabolism and aging.

Entities:  

Keywords:  FGF21; GH; Mixed meal; β-Klotho

Mesh:

Substances:

Year:  2021        PMID: 33770382     DOI: 10.1007/s12020-021-02700-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  4 in total

1.  Familial dwarfism due to a novel mutation of the growth hormone-releasing hormone receptor gene.

Authors:  R Salvatori; C Y Hayashida; M H Aguiar-Oliveira; J A Phillips; A H Souza; R G Gondo; S P Toledo; M M Conceicão; M Prince; H G Maheshwari; G Baumann; M A Levine
Journal:  J Clin Endocrinol Metab       Date:  1999-03       Impact factor: 5.958

2.  Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout life.

Authors:  M H Aguiar-Oliveira; M S Gill; E S de A Barretto; M R Alcântara; F Miraki-Moud; C A Menezes; A H Souza; C E Martinelli; F A Pereira; R Salvatori; M A Levine; S M Shalet; C Camacho-Hubner; P E Clayton
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

Review 3.  Fibroblast growth factor 21: a regulator of metabolic disease and health span.

Authors:  Ting Xie; Po Sing Leung
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-05-30       Impact factor: 4.310

4.  Aging is associated with increased FGF21 levels but unaltered FGF21 responsiveness in adipose tissue.

Authors:  Joan Villarroya; José M Gallego-Escuredo; Alejando Delgado-Anglés; Montserrat Cairó; Ricardo Moure; Ma Gracia Mateo; Joan C Domingo; Pere Domingo; Marta Giralt; Francesc Villarroya
Journal:  Aging Cell       Date:  2018-07-24       Impact factor: 9.304

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.